Last Updated: 15 Sep 2024
Executive Summary
Notable Labs Inc. (NTBL) is a clinical-stage platform therapeutic company focused on developing predictive precision medicine for cancer patients. Despite a challenging financial performance with negative EBITDA and EPS, the company has a promising pipeline of therapeutic candidates. Analysts have a mixed outlook on NTBL, with two Buy ratings and no Strong Buy or Sell ratings. The latest stock price of $0.48 is below the 52-week high of $10.08 but above the 52-week low of $0.45.
Company Overview
Notable Labs is headquartered in Foster City, California, and has a market capitalization of $4.62 million. The company's mission is to transform cancer care by empowering physicians with predictive precision medicine. Notable Labs' proprietary platform, MAP, combines machine learning and genomic sequencing to identify the most effective treatments for individual cancer patients.
Fundamental Analysis
Revenue: NTBL reported revenue of $313,000 for the trailing twelve months (TTM).
EBITDA: The company's EBITDA was negative $15.12 million for the TTM.
EPS: Diluted EPS for the TTM was negative $1.09.
Book Value: NTBL's book value per share is $0.744.
Profitability: The company has a negative profit margin and operating margin.
Technical Analysis
52-Week High/Low: $10.08/$0.45
Moving Averages: The 50-day moving average is $0.573, and the 200-day moving average is $1.236.
Price-to-Sales Ratio: The price-to-sales ratio (TTM) is 14.75.
Price-to-Book Ratio: The price-to-book ratio is 0.642.
Short Term Outlook
The short-term outlook for NTBL is mixed. The stock price is trading near its 52-week low, and the company has yet to demonstrate profitability. However, the company's promising pipeline of therapeutic candidates could provide potential upside in the future.
Long Term Outlook
The long-term outlook for NTBL is more positive. The company's MAP platform has the potential to revolutionize cancer treatment by providing personalized and effective therapies for patients. If NTBL can successfully commercialize its pipeline, it could become a major player in the precision medicine market.
Analyst Recommendations
Two analysts have issued Buy ratings on NTBL. The average analyst target price is $9.00, which represents a significant premium to the current stock price.
